5-HTP — Research Profile

Short-to-medium term daily use (weeks to a few months) at 100-300 mg/day is generally well-tolerated. However, long-term daily use raises theoretical concerns about dopamine/norepinephrine depletion, since 5-HTP exclusively boosts serotonin. Some practitioners recommend cycling (e.g., 5 days on, 2 off) or combining with L-tyrosine to maintain catecholamine balance.

This is potentially dangerous without medical supervision. Combining 5-HTP with SSRIs, SNRIs, MAOIs, or other serotonergic drugs can cause serotonin syndrome — a serious and potentially life-threatening condition. Never combine 5-HTP with prescription serotonergic medications without explicit guidance from your prescribing physician.

Clinical evidence suggests it can reduce appetite. A study by Cangiano et al. (1992)^[2] found 750 mg/day 5-HTP reduced caloric intake by approximately 400 calories daily and promoted earlier satiety in obese women. The mechanism is serotonin-mediated appetite regulation. However, effects are modest, and 5-HTP works best as one component of a comprehensive weight management approach.

5-HTP is sold almost entirely as oral capsules or tablets of Griffonia simplicifolia extract, and that is the form used across the clinical trials. No study has compared delivery forms to show one is more effective, so the practical differentiator is purity and dose rather than form. Splitting the daily amount into smaller doses is the main way to improve tolerability.

The strongest human signals are for appetite/weight and sleep. At 900 mg/day, obese adults showed early satiety, reduced carbohydrate intake, and significant weight loss, and 100 mg/day cut fat mass over 8 weeks in exercise-trained adults. A 12-week trial found improved subjective sleep in poor sleepers, and another 12-week study reported modest gains in cognitive and depression scores in older adults. These trials are small, so the benefits are promising rather than definitively established.

No standardized dose is established, and trials span a wide range by goal. Sleep, mood, and body-composition studies used 100 mg/day, while appetite and weight-loss studies used up to 900 mg/day in divided doses. Because GI side effects become more common above 100 mg, a lower divided dose is the better-tolerated starting point.

Timing has not been directly compared in trials, so recommendations are inferred from the intended effect. Sleep studies dosed 5-HTP daily, and evening use aligns with its role as a precursor to serotonin and melatonin, whereas appetite studies used divided doses across the day. Splitting the daily amount into smaller doses is also a reasonable way to limit the dose-dependent nausea that appears above 100 mg.

The most common side effects are gastrointestinal - nausea, vomiting, and diarrhea - and Memorial Sloan Kettering's monograph lists headache, insomnia, and palpitations as less common. The GI effects are dose-dependent, becoming more likely above 100 mg, and generally ease once a steady dose is reached. In a controlled primary-fibromyalgia trial, only mild and transient side effects were reported.

The key interaction is with serotonergic and related drugs: Memorial Sloan Kettering's monograph warns that combining 5-HTP with SSRIs, tricyclic antidepressants, or MAO inhibitors raises the risk of serotonin syndrome, and it documents case reports of harm when 5-HTP was combined with the MAOI antibiotic linezolid and with carbidopa. No confirmed human serotonin-syndrome case has been published from 5-HTP alone, but the mechanism is well established, so anyone on antidepressants should not add it without medical supervision.

5-HTP is most relevant to adults exploring non-prescription options for sleep quality, appetite or weight control, or low mood, where small trials show benefit. It is not appropriate for people already taking serotonergic antidepressants or other serotonin-raising drugs because of interaction risk. Evidence in children, pregnancy, and use beyond about 12 weeks is lacking, so those groups should avoid it.

5-HTP raises serotonin within hours, but measurable clinical effects build over weeks. In a 12-week trial in older adults, poor sleepers showed significant improvement in subjective sleep scores only by week 12, and a separate 12-week study found cognitive and depression scores improved over the same period. Appetite effects appear sooner: early satiety and weight loss were seen within each 6-week treatment period at 900 mg/day.

Controlled 5-HTP trials have run only to about 12 weeks, so longer-term safety in humans is not well characterized. A comprehensive review notes that despite worldwide use of 5-HTP over roughly the last two decades, no definitive case of toxicity has emerged apart from a single unresolved report. The main practical limit on daily use is dose-dependent gastrointestinal upset rather than any cumulative organ toxicity.

No tolerable upper limit has been established for 5-HTP. Nausea and vomiting become more likely at doses above 100 mg and are dose-dependent, and although trials have used up to 900 mg/day for appetite control, GI complaints are the main limiting factor. The more serious concern is excess serotonin signaling when 5-HTP is stacked with serotonergic drugs, not overdose from 5-HTP taken alone.

The combination that matters for safety is with other serotonin-raising products: Memorial Sloan Kettering's integrative-medicine monograph advises against pairing 5-HTP with St. John's wort or SAMe because stacking serotonergic agents raises the risk of serotonin syndrome. No human serotonin-syndrome case has been published from 5-HTP taken alone, and the review notes no definitive toxicity cases, but the mechanism is well established, so serotonergic supplement stacks warrant caution. With non-serotonergic supplements there is no specific documented interaction.

Commercial 5-HTP is extracted from the seeds of the West African plant Griffonia simplicifolia. Because the 1989 eosinophilia-myalgia outbreak linked to L-tryptophan was traced to a manufacturing contaminant from a single producer (Showa Denko) rather than the molecule itself, third-party purity and contaminant testing is the meaningful quality signal. There is no active-percentage standardization to verify the way there is for botanical extracts.